NVRO Nevro Corp. Given Rating Of “Buy”


NVRO Nevro Corp. is a medical device company. Its main products are provided for chronic pain patients’ suffering. It is provided in the United States as well as internationally. The firm does both commercialize and develop Senza, a stimulation system for the spinal cord. It is a forum for evidence-based neuromodulation to continue to treat chronic pain.

On Friday, NVRO opened with a rate of $175.96. Over sixteen research analysts have weighed in with their recommendation on the rates of the company. Three researchers have given the prices a rating of “hold.” The eleven others among them have given the ratings a “buy” suggestion. The yearly average price target for the past year is $177.77, as reported by some brokerages.

Analysts’ Reports On NYSE: NVRO

Several analysts reported about NVRO’s prices. The target price for Nevro was raised by SVB Leerink. It was given a rate of $210, climbing from a previous $190.00 and getting an “outperform” recommendation. Another analyst upgraded the target price by $20.00, summing up as $200.00. It also rated the firm an “outperform.” This report was given on the 5th of January, on Tuesday. 

The company received yet another hike from TheStreet on Wednesday, the 18th of November. NVRO got a “c-” climbing from a previous rating of “d+.” The price was upgraded for the fourth time by Canaccord Genuity on Tuesday. It was given a rating of “buy,” rising higher, reaching the price value of $203.00 from an older value of $167.00. The final recommendation came from OTR Global on the 21st of October Wednesday. The rating given was a “positive.” 

The average price for a 50 day moving is $172.63. The same average for a two-hundred day moving is $151.40. The 52-week low and high are $65.05 and $188.14, respectively. The market capital for NVRO is a whopping $6.06 billion.